3. Role of cytokines in the syndrome of heart failure

Internal Medicine

Volumn 35, Issue 1, 1996, Pages 60-63

  Sasayama, Shigetake ^a   Matsumori, Akira ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cardiomyopathy; Immunomodulation; Inotropic agent; Myocarditis; NK cell; Survival rate; TNF

Indexed keywords

AMRINONE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR ALPHA; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; PHOSPHODIESTERASE INHIBITOR; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; HEART FAILURE; IMMUNOMODULATION; MALE; MOUSE; MYOCARDITIS; NATURAL KILLER CELL; NONHUMAN; SURVIVAL; ANIMAL; ARTICLE; CONGESTIVE HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-AGONISTS; AMRINONE; ANIMALS; CARDIOTONIC AGENTS; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; KILLER CELLS, NATURAL; MYOCARDITIS; PHOSPHODIESTERASE INHIBITORS; QUINOLINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029918974     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.35.60     Document Type: Article

References (14)

1. Matsumori A, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72: 561, 1994.
2. Maury CP, Teppo A-M. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J Intern Med 225: 333, 1989.
3. Levine B, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236, 1990.
4. Doyama K, et al. Expression of tumor necrosis factor (TNF) is augmented in the right atrium of human failing hearts. Circulation 90: I, 1994 (Abstract).
5. Gulick T, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA 86:6753, 1989.
6. Balligand JL, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Proc Natl Acad Sci USA 90: 347, 1993.
7. Finkel MS, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (Wash. DC) 257: 387, 1992.
8. Yamada T, et al. Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 89: 846, 1994.
9. Packer M for The Promise Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468, 1991.
10. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther 6: 15, 1992.
11. OPC-8212 Multicenter Research Group: A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 4: 19, 1990.
12. Matsui S, et al. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest 94: 1212, 1994.
13. Shioi T, et al. Inhibition of cytokine production by anew inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sciences 54: PL11, 1994.
14. Matsui S, et al. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Science 55: 1735, 1994.